

1 **Bronchoalveolar lavage metabolome dynamics reflect underlying disease and chronic**  
2 **lung allograft dysfunction**

3  
4 Christian Martin <sup>a</sup>, Kathleen S. Mahan <sup>b</sup>, Talia D. Wiggen <sup>c</sup>, Adam J. Gilbertsen <sup>c</sup>, Marshall I.  
5 Hertz <sup>b</sup>, Ryan C. Hunter <sup>c\*</sup> and Robert A. Quinn <sup>a\*</sup>

6 <sup>a</sup> Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing,  
7 Michigan, USA.

8 <sup>b</sup> Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine,  
9 University of Minnesota, Minneapolis, Minnesota, USA.

10 <sup>c</sup> Department of Microbiology and Immunology, University of Minnesota Medical School,  
11 Minneapolis, Minnesota, USA.

12 \* Denotes co-corresponding authors: Ryan C. Hunter, Department of Microbiology and  
13 Immunology, University of Minnesota Medical School, 689 23rd Ave SE, Minneapolis,  
14 Minnesota, 55455, [rchunter@umn.edu](mailto:rchunter@umn.edu); Robert A. Quinn, 603 Wilson Rd. Rm 120, Department  
15 of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan,  
16 48824, [quinnrob@msu.edu](mailto:quinnrob@msu.edu)

17  
18 **Abstract**

19 **Background** Progression of chronic lung disease often leads to the requirement for a lung  
20 transplant (LTX). Despite improvements in short-term survival after LTX, chronic lung allograft  
21 dysfunction (CLAD) remains a critical challenge for long-term survival. This study investigates  
22 the relationship between the metabolome of bronchoalveolar lavage fluid (BALF) from subjects  
23 post-LTX with underlying lung disease and CLAD severity.

24 **Methods** Untargeted LC-MS/MS metabolomics was performed on 960 BALF samples collected  
25 over 10 years from LTX recipients with alpha-1-antitrypsin disease (AATD, n=22), cystic fibrosis  
26 (CF, n=46), chronic obstructive pulmonary disease (COPD, n = 79) or pulmonary fibrosis (PF,  
27 n=47). Datasets were analyzed using machine learning and multivariate statistics for  
28 associations with underlying disease and final CLAD severity.

29 **Results.** BALF metabolomes varied by underlying disease state, with AATD LT recipients being  
30 particularly distinctive (PERMANOVA,  $p=0.001$ ). We also found a significant association with  
31 the final CLAD severity score (PERMANOVA,  $p=0.001$ ), especially those with underlying CF.  
32 Association with CLAD severity was driven by changes in phosphoethanolamine (PE) and  
33 phosphocholine lipids that increased and decreased, respectively, and metabolites from the  
34 bacterial pathogen *Pseudomonas aeruginosa*. *P. aeruginosa* siderophores, quorum-sensing

35 quinolones, and phenazines were detected in BALF, and 4-hydroxy-2-heptylquinoline (HHQ)  
36 was predictive of the final CLAD stage in samples from CF patients ( $R=0.34$ ;  $p\leq 0.01$ ).  
37 Relationships between CLAD stage and *P. aeruginosa* metabolites were especially strong in  
38 those with CF, where 61% of subjects had at least one of these metabolites in their first BALF  
39 sample after transplant.

40 **Conclusions:** BALF metabolomes after LTX are distinctive based on the underlying disease  
41 and reflect final CLAD stage. In those with more severe outcomes, there is a lipid transition from  
42 PC to predominantly PE phospholipids. The association of *P. aeruginosa* metabolites with  
43 CLAD stages in LTX recipients with CF indicates this bacterium and its metabolites may be  
44 drivers of allograft dysfunction.

45

46 **Key messages:** Despite the high prevalence of CLAD among LTX recipients, its pathology is  
47 not well understood, and no single molecular indicator is known to predict disease onset. Our  
48 machine learning metabolomic-based approach allowed us to identify patterns associated with a  
49 shift in the lipid metabolism and bacterial metabolites predicting CLAD onset in CF. This study  
50 provides a better understanding about the progression of allograft dysfunction through the  
51 molecular transitions within the transplanted lung from the host and bacterial pathogens.

52

53 **Key words** Metabolomics; cystic fibrosis; bronchioalveolar lavage fluids; chronic lung allograft  
54 dysfunction, chronic lung diseases; phosphoethanolamine; phosphocholine; quinolones,  
55 *Pseudomonas aeruginosa*.

56

57 **Word count:** 3,452

58

59

60

## 61 **Introduction**

62 Lung transplantation (LTX) is a therapeutic option for patients who develop progressive  
63 and severe chronic lung disease [1]. However, chronic lung allograft dysfunction (CLAD)  
64 remains a major barrier to long-term LTX patient survival, as it affects 50% of patients at five  
65 years post-transplantation [2,3]. Bronchiolitis obliterans syndrome (BOS), a crucial phenotypic  
66 manifestation of allograft dysfunction [4,5], is used as a scaled measure of disease progression  
67 (i.e., CLAD stage) [6]. Notoriously a heterogenous disease, BOS severity scores were recently  
68 updated in 2019 [6] to better characterize the stages of severity experienced by LTX recipients.  
69 These CLAD stages can occur post-LTX in patients with different pre-LTX lung diseases such  
70 as alpha-1-antitrypsin deficiency disease (AATD), cystic fibrosis (CF), chronic obstructive  
71 pulmonary disease (COPD), and pulmonary fibrosis (PF) [7–10].

72 Bronchoalveolar lavage fluid (BALF) is a valuable sample type for studying pathological  
73 characteristics that develop after LTX due to the direct proximity of BALF sample origin to the  
74 site of stress and/or injury in the lung [11]. Metabolites detected within BALF can be indicative of  
75 physiological processes of disease progression, microbial lung burden, and possibly, allograft  
76 rejection [12,13]. However, there are few studies of BALF metabolomes describing the  
77 composition, microbial virulence factors, amino acids, lipids, and a myriad of pharmaceuticals  
78 [14–17].

79 Untargeted mass spectrometry (MS)-based metabolomics allows exploration of the  
80 chemical diversity associated with a wide range of biological samples [18,19]. However,  
81 navigating the diverse chemical data generated in untargeted metabolomics studies, in which a  
82 large proportion of detectable metabolites are unknown, remains challenging [18,19]. Advances  
83 in bioinformatic analyses of MS data have enabled a more comprehensive interpretation of  
84 biological information contained within these highly technical and large datasets. For example,  
85 the Global Natural Products Social molecular networking web platform (GNPS) has simplified  
86 the exploration of the chemical space of metabolomes. GNPS is a tandem mass spectrometry  
87 (MS/MS) automated data organizational tool that enables comparisons of MS/MS fragmentation  
88 patterns among samples to cluster and visualize related molecules in a spectral network [20,21].  
89 GNPS can be paired with metabolite feature quantification algorithms to create a  
90 comprehensive workflow for untargeted metabolomics of clinical samples [20,22]. In this study,  
91 we applied this approach to 960 BALF samples collected longitudinally from 194 LTX recipients  
92 to determine whether post-transplant BALF metabolomes reflect the underlying disease  
93 diagnosis; and whether specific molecular signatures correlate with allograft dysfunction.

94

## 95 **Materials and Methods**

### 96 **Study Design, Subjects, and BOS-Grading.**

97 Subjects with AATD, CF, COPD, and IPF who underwent lung transplantation at the  
98 University of Minnesota consented to have a portion of their post-LTX BALF used for research.  
99 BALF was collected over a 10-year period from 2002 to 2012 as a routine procedure per  
100 transplant protocol or if undergoing diagnostic BALF collection due to clinical indications, such  
101 as new radiographical changes, new respiratory symptoms, or a decrease in FEV<sub>1</sub>. Inclusion  
102 criteria were ≥ 18 years of age; diagnosis of AATD, CF, COPD, or PF; and receipt of a bilateral  
103 or single lung transplant. Exclusion criteria were < 18 years of age and the inability to provide  
104 consent and/or tolerate the BALF procedure. Clinical characteristics of subjects in this study,  
105 including disease progression scores and samples collected for each, are displayed in Table 1  
106 and Table S1. BOS-grade was recorded for patients based on the changes in their forced  
107 expiratory volume in one second (FEV<sub>1</sub>), initially determined using definitions of the International  
108 Society for Heart and Lung Transplantation (ISHLT) [23], and updated here to reflect current  
109 CLAD definitions [6]. The final CLAD stage was known for each patient, while some measures  
110 were determined after sample collection ceased. This protocol was approved by the University  
111 of Minnesota IRB (STUDY00004547).

112

### 113 **Bronchoalveolar lavage sampling material.**

114 Bronchoalveolar lavage fluid (BALF) was collected via orotracheal or nasotracheal  
115 bronchoscopy. Sterile saline was instilled into a subsegmental bronchus after advancement and  
116 occlusion of the airway lumen. BALF was separated into ~1.5 mL aliquots and frozen at -80 °C  
117 for further untargeted metabolomic analysis (see supplementary methods). All 960 samples  
118 were included for analysis of variation (ANOVA) among underlying disease types and  
119 associations with final CLAD stages.

120

### 121 **Organic extraction and LC-MS/MS analysis**

122 Methanolic extracts of 960 BALF samples (50:50 v/v) were analyzed on a Thermo  
123 QExactive™ mass spectrometer coupled to a Vanquish Ultra-High-Performance Liquid  
124 Chromatography (UHPLC) system (ThermoFisher) (see supplementary methods) [21,24].  
125 Subsequently, feature-based molecular networking (FBMN) was performed with a parent and  
126 fragment mass ion tolerance of 0.02 Da, a cosine score of 0.65, and a minimum matched peaks  
127 minimum of 4 [22]. FBMN is publicly available at  
128 <https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=756456ac794d48b0bba80dbe28e0de66>,



129 and raw data files are available in the MASSIVE data repository as [MSV000085760](https://massive.ucsf.edu/MSV000085760). Data  
130 curation consisted of removing metabolites detected in blanks and removal of known  
131 pharmaceuticals and their related nodes in the molecular network (see supplementary methods,  
132 Figure S1, and Table S2). Presence/absence frequency and rank abundance of all molecular  
133 features were calculated after creating a cutoff by summing the relative abundances of features  
134 above  $10 \times 10^5$  abundance in samples obtained from subjects with AATD, CF, COPD, or IPF.

135

## 136 **Statistical analysis**

137 Variations in metabolomic data associated with underlying disease type and the final  
138 CLAD stage for each subject were assessed using beta-diversity metrics and tested for  
139 significance with permutational multivariate analysis of variance (PERMANOVA). Metabolome  
140 variation was further assessed using random forest (RF) classification and regression analysis  
141 (numerical CLAD stages, 0 to 4). A Bray-Curtis dissimilarity matrix was calculated on the entire  
142 metabolome and used to generate principal coordinate analysis (PCoA) plots through the in-  
143 house tool ClusterApp and visualized in EMPeror [25]. PERMANOVA tests were performed for  
144 diseases and CLAD stages (as a categorical variable) with subject-source as an interacting  
145 factor to account for variation in the number of samples per subject. Post-hoc tests among  
146 disease types were performed with R packages Devtools and Vegan (pairwise-adonis) [26,27].  
147 Variable importance plots from both RF approaches were used to identify metabolites driving  
148 the variation observed. Pearson correlations were used to determine relationships between  
149 metabolite abundance and final CLAD stages, as well as the correlation of *P. aeruginosa*  
150 metabolites with its relative abundance determined using 16S rRNA sequence data from the  
151 same samples. 16S rRNA sequence data were generated using bacterial genomic DNA  
152 extracted from each sample, sequencing the V4 region using Illumina MiSeq TruSeq 2x300  
153 paired-end technology, and sequence analysis in R as previously described [28]. The relative  
154 abundance of *P. aeruginosa* was determined using DADA2 [29]. R packages random forest,  
155 vegan and ggplot2 were also used for these analyses [30–32] (see supplementary methods).

156

## 157 **Results**

### 158 **Sample collection and clinical design.**

159 The two primary objectives for this study were: i) to determine if the metabolome of  
160 BALF collected after LTX was associated with the underlying pre-LTX lung diagnosis, and ii) if  
161 the data were associated with measures of CLAD severity across all subjects and within each  
162 underlying disease type. The dataset comprised longitudinal BALF samples (n = 960) collected

163 over a 10-year period from subjects ( $n = 194$ ) with one of four underlying conditions prior to  
164 transplant; AATD ( $n = 22$ ), CF ( $n = 46$ ), COPD ( $n = 79$ ), and PF ( $n = 47$ ). Clinical parameters  
165 and patient demographic information are presented in Table 1. Subjects developed CLAD at  
166 different times and to varying degrees during the collection period. The final BOS-grade of all  
167 subjects was known, even when this measure was recorded after BALF collection had ceased.  
168 Thus, metabolome data variation was tested against this final BOS-grade measure.

169

### 170 **BALF metabolome variation based on the underlying lung disease type pre-transplant**

171 Since BALF samples were obtained via bronchoscopy, numerous drugs and xenobiotics  
172 were identified in the dataset. We reasoned that these molecules could confound underlying  
173 biologically significant trends, so they were removed from the metabolome data using Global  
174 Natural Product Social (GNPS) library searching and molecular networking to identify known  
175 and chemically related pharmaceuticals in the GNPS libraries. After filtering pharmaceuticals  
176 and sample contaminants (detected in controls), the entire BALF data set included 4755  
177 molecular features, of which 361 had a spectral match to known compounds in GNPS libraries  
178 [21].

179 PCoA ordination of the entire dataset, colored by pre-transplant disease diagnosis,  
180 revealed significant differences between AATD, CF, COPD, and PF cohorts (PERMANOVA  $F =$   
181  $3.91$ ,  $p = 0.001$ , Figure 1a). Additionally, post-hoc testing showed significant pairwise  
182 differences between diseases (Table 2), suggesting that allograft metabolomes are dependent,  
183 in part, on the underlying disease of the transplant recipient. This unique disease signature was  
184 especially marked in subjects with AATD, as evidenced by its low random forest (RF)  
185 classification error (13.3%, Table S3) and separation by PCoA clustering (Figure 1a). We then  
186 used supervised RF classification analysis to identify metabolites that most strongly  
187 distinguished BALF samples by the underlying disease. The top 10 metabolites driving  
188 differences between groups included phenylalanine, phosphocholines, and other lipids. Notably,  
189 phenylalanine was particularly abundant in subjects with underlying AATD (pairwise p-value CF  
190  $p = 2.9 \times 10^{-11}$ , COPD  $p = 4.7 \times 10^{-14}$ , and IPF  $p = 3.1 \times 10^{-13}$ ) (Figure 1b, Figure S2).

191 To further understand the nature of the unique BALF metabolome in LTX recipients with  
192 AATD, we analyzed metabolite presence/absence to determine the degree of chemical sharing  
193 among underlying diseases. Although most metabolites were shared across all four diseases,  
194 AATD unexpectedly had fewer molecules shared with the other diseases (either one other, or  
195 two others, Figure 1c). Rank abundance curves of the metabolome revealed that AATD had

196 fewer overall metabolites, and these were less abundant than the other three disease types  
197 (Figure 1a,d).

198

### 199 **Longitudinal allograft metabolomes are associated with CLAD severity outcomes**

200 Each subject's final CLAD stage was then used to assess the relationship between the  
201 entire longitudinal metabolome dataset and disease severity (n = 960). PERMANOVA  
202 (categorical CLAD stage, F = 4.023, p = 0.001) and RF regression (linearized CLAD stage,  
203 variance explained = 11.08%) revealed an overall association of the final CLAD stage with  
204 collective longitudinal metabolome composition (Figure 2a). When tested separately on each  
205 pre-LTX disease diagnosis, CLAD stages maintained their categorical significance for all but IPF  
206 (Figure 2b). RF regression showed that LTX recipients with underlying CF had the strongest  
207 association of their BALF metabolome variation with numerical CLAD stages (% variance  
208 explained = 34.04), followed by COPD (14.36) and markedly less variation in IPF (4.65) and  
209 AATD (3.16) (Figure S3). These results demonstrate a significant relationship between the  
210 BALF metabolome after LTX and the final CLAD stage, which was particularly strong among  
211 individuals with CF.

212

### 213 **Altered phospholipids and *P. aeruginosa*-derived molecules drive association with the** 214 **final CLAD stage**

215 The association between CLAD stage and longitudinal metabolome composition,  
216 particularly among CF subjects, motivated further analyses of specific metabolites that most  
217 strongly influenced trends in the dataset. Variable importance plots from the RF analysis of the  
218 entire dataset and each disease analyzed separately revealed several metabolites of interest  
219 (Figure S3, S4). Molecular networking was then used to help annotate and identify these and  
220 related molecules. With this approach, we identified four clusters ('molecular families') of  
221 interest, including phosphoethanolamine (molecular family I), phosphocholine (molecular  
222 families II and III), and quinolone-like-molecules (molecular family IV, Figure S5). The molecular  
223 family I included the phospholipids lysophosphoethanolamine (lysoPE) 18:0/0:0 (*m/z* 482.3225  
224 [M+H]<sup>+</sup>, C<sub>23</sub>H<sub>49</sub>NO<sub>7</sub>P, 3.4 ppm error) and lysoPE 18:1/0:0 (*m/z* 480.3073 [M+H]<sup>+</sup>, C<sub>23</sub>H<sub>47</sub>NO<sub>7</sub>P,  
225 2.40 ppm error). Molecular family II included phosphatidylcholine 16:0/14:0 (*m/z* 728.5183  
226 [M+Na]<sup>+</sup>, C<sub>38</sub>H<sub>76</sub>NO<sub>8</sub>P, 2.42 ppm error). Molecular family III corresponds to PC 16:0/18:0 (*m/z*  
227 780.5529 [M+Na]<sup>+</sup>, C<sub>42</sub>H<sub>80</sub>NO<sub>8</sub>P -2.20 ppm error). Finally, in molecular family IV, we identified 4-  
228 hydroxy-2-heptylquinolone (HHQ, *m/z* 244.1689 [M+H]<sup>+</sup>, C<sub>16</sub>H<sub>22</sub>NO 2.8 ppm error), a  
229 *Pseudomonas aeruginosa*-derived quinolone and known quorum sensing metabolite that plays

230 an integral role in the gene expression and physiology of this opportunistic pathogen (Figures  
231 S5 and S6) [33].

232 We then plotted the relationship between the feature abundances of each metabolite of  
233 interest with the final CLAD stages across the entire dataset. Both lysoPE(18:0/0:0) and  
234 lysoPE(18:1/0:0) significantly increased with disease progression (Pearson  $r = 0.23$ ,  $p = 6.9e-13$   
235 , and  $r = 0.16$ ,  $p = 0.017$ , respectively). In contrast, phosphocholine molecules PC (16:0/14:0)  
236 and PC(16:0/18:0) decreased as final disease severity increased (Pearson  $r = -0.22$ ,  $p = 4.4e-$   
237  $10$  and  $r = -0.19$ ,  $p = 1.9e-08$ , respectively). Linear regression analysis of HHQ abundance and  
238 individual subjects' final CLAD stage also showed a significant increase as allograft dysfunction  
239 worsened (Pearson  $r = 0.14$ ,  $p = 0.0035$ ) (Figure 3a).

240 Finally, we parsed the molecular dynamics of these molecules based on the underlying  
241 disease and identified unique trends within each condition. LysoPE (18:0/0:0) significantly  
242 increased with disease progression in CF (Pearson  $r = 0.33$ ,  $p \leq 0.001$ ), followed by COPD ( $r =$   
243  $0.28$ ,  $p \leq 0.001$ ) and IPF ( $r = 0.14$   $p \leq 0.001$ ), but not in AATD. LysoPE (18:1/0:0) abundance  
244 was positively correlated with IPF only (Pearson  $r = 0.42$ ,  $p \leq 0.001$ ). The feature abundance of  
245 PC (16:0/14:0) significantly decreased as disease severity worsened only in CF and COPD  
246 (Pearson  $r = -0.41$ ,  $p \leq 0.001$  and  $r = -0.28$   $p \leq 0.001$ , respectively), whereas PC (16:0/18:0)  
247 significantly decreased in CF, COPD and IPF (Pearson  $r = -0.27$ ,  $p \leq 0.001$ ;  $r = -0.24$ ,  $p \leq 0.001$ ;  
248 and  $r = -0.19$   $p \leq 0.001$ , respectively). Neither of these molecules varied with CLAD stages in  
249 AATD. In the case of HHQ, its molecular abundance significantly increased with disease  
250 progression in CF (Pearson  $r = 0.34$ ,  $p \leq 0.001$ ) (Figure 3b) but not the others, indicating that  
251 the trend seen in the complete dataset was driven by the CF samples.

252

### 253 ***Pseudomonas aeruginosa* molecular signatures in subjects with CF after LTX**

254 The association of HHQ with CLAD severity led to further analysis of the diversity of *P.*  
255 *aeruginosa* metabolites and their relationship with clinical outcomes, particularly in those  
256 subjects with CF. Molecular networking allowed us to identify additional molecular signatures  
257 from the pathogen, including 2-heptyl-4-quinolone-N-oxide (HQNO;  $m/z$  260.1645 [M+H]<sup>+</sup>,  
258 C<sub>16</sub>H<sub>22</sub>NO<sub>2</sub>; 10.67 ppm), 2-nonyl-4-quinolone (HNQ;  $m/z$  270.1852 [M+H]<sup>+</sup>, C<sub>17</sub>H<sub>24</sub>NO; 7.45  
259 ppm), pyocyanin ( $m/z$  211.0866 [M+H]<sup>+</sup>, C<sub>13</sub>H<sub>11</sub>N<sub>2</sub>O; 5.64 ppm) and pyochelin ( $m/z$  325.0675  
260 [M+H]<sup>+</sup>, C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>S<sub>2</sub>; 10.46 ppm). Molecular network node mapping based on disease showed  
261 that the entire molecular family of quinolones and pyochelin were enriched in subjects with  
262 underlying CF (pie charts within nodes) (Figure 4a). We were therefore interested in determining  
263 when these molecules were detected in the longitudinal BALF samples of each subject. We

264 found that ~60% of samples (n = 46) from subjects with CF were positive for at least one *P.*  
265 *aeruginosa* molecule in the first BALF sample collected (Figure 4b), and the abundances were  
266 particularly high at this first-time point (Figure 4c). This proportion of positive samples stayed  
267 relatively stable, with a slight decrease in successive BALFs collected (Figure 4b). Some  
268 subjects showed acquisition of *P. aeruginosa* molecules as time since transplant progressed,  
269 whereas most initially had high abundances and a subsequent decrease (Figure 4c). However,  
270 a Pearson correlation between the abundance of these molecules and the time since LTX was  
271 not significant (R = 0.074; p = 0.18). The abundance of these molecules did increase (R = 0.34;  
272 p = 0.0046) with the relative abundance of *Pseudomonas* sp. (Figure 4d,e).

273

## 274 Discussion

275 In this study, we applied untargeted metabolomics to 960 BALF samples from patients  
276 who had undergone LTX for chronic lung disease. We had a particular interest in metabolite  
277 variation based on the underlying disease and the “gold standard” measure of disease severity  
278 (i.e., CLAD stage). The post-LTX metabolome data differed based on the underlying disease,  
279 with the unique profile found in AATD. Other chronic lung diseases (CF, COPD, PF) were  
280 significantly different from one another but more difficult to distinguish overall. The uniqueness  
281 of AATD was driven by differences in aromatic amino acids (phenylalanine), an overall lack of  
282 shared molecules with the other diseases, and a lower abundance of metabolite features  
283 overall. We note that all four underlying conditions have unique etiologies, and the findings here  
284 indicate that, somewhat unexpectedly, the chemical environment of the lung allograft reflects  
285 the initial disease of the recipient, particularly in the case of AATD. The high abundance of  
286 phenylalanine in allografts from subjects with AATD may reflect increased proteolysis, which is  
287 a hallmark of this disease [23], though further research is needed to confirm this hypothesis.

288 The overall annotation rate of MS/MS spectra in our dataset was 7.6%, which is not  
289 uncommon in untargeted metabolomics studies [34]. Low levels of metabolite identification are a  
290 known challenge in metabolomics and can limit the ability to infer mechanistic associations with  
291 disease severity, although annotation rates in untargeted metabolomics experiments are  
292 increasing as new search algorithms and databases become available [22,35–37].  
293 Nevertheless, there is considerable power in using comprehensive molecular data from  
294 untargeted metabolomics experiments to identify biological trends, even when the molecular  
295 structures are not known. An important step for this approach, which we performed here, is the  
296 removal of pharmaceuticals and xenobiotics, which can be highly abundant and overwhelm  
297 underlying biological signals. The molecular networking algorithm applied here greatly increases

298 the ability to ‘clean up’ the metabolome by enabling the identification and visualization of  
299 pharmaceuticals and their chemical relatives.

300 Bronchoalveolar lavage fluids have been used recently for describing molecular changes  
301 in lipids and metabolites after LTX [16]; however, the association of these compounds with  
302 allograft dysfunction has not been addressed. One of the strongest signatures in our  
303 metabolomic data was the association of the metabolome with the final CLAD stage of each  
304 subject, and this was particularly strong for those with CF. In this case, many of the molecular  
305 features driving the association had annotations in the GNPS libraries, and they were primarily  
306 phospholipids and bacterial metabolites. A closer analysis of these molecules identified a  
307 transition in lipid species associated with an increased final CLAD stage. Subjects whose final  
308 CLAD severity was lower had more abundant phosphocholine lipids in their longitudinal BALF  
309 metabolome, while those with more severe CLAD outcomes had a higher abundance of  
310 phosphoethanolamine lipids. This phospholipid lipid transition may indicate a disruption in  
311 airway surface liquid (ASL) in the transplanted lung as the disease progresses or alterations in  
312 lipid metabolism. ASL is mainly composed of phospholipids (90%) and proteins (10%), which  
313 are products of surface and submucosal gland epithelia and resident phagocytic cells [38].  
314 Approximately 70–80% of ASL lipids are dipalmitoyl phosphatidylcholine (DPPC) [39,40] and PE  
315 is a major phospholipid in lung surfactant. The increase in PE abundance associated with CLAD  
316 severity found here may be due to the influx of neutrophils or other inflammatory cells containing  
317 this lipid. Another potential source is allograft-colonizing microbiota, as PE lipids are known to  
318 be a component of bacterial membranes [41,42].

319 Detection of quorum-sensing metabolites from *P. aeruginosa* in BALF and the  
320 association of HHQ with final CLAD severity implicates the bacterium and its metabolism in  
321 disease progression. These molecules were particularly prevalent in subjects with underlying  
322 CF, where this bacterium is a known opportunistic pathogen responsible for chronic airway  
323 infection [43–45] [43]. *P. aeruginosa* regulates the production of its virulence factors through its  
324 quorum sensing system, which plays an important role in CF pathogenesis. Multiple quinolones  
325 from *P. aeruginosa* such as HQNO, HNQ, and PQS (Pseudomonas quinolone signal), were  
326 detected in BALF, as were other two other small molecule virulence factors pyocyanin and  
327 pyochelin. Quorum sensing is mediated through N-acyl-homoserine lactones (AHLs) and alkyl  
328 quinolones (AQ) [46], the latter of which were detected in this study. The correlation between  
329 the abundance of these molecules and the final CLAD stage indicates they could potentially be  
330 explored as biomarkers of bacterial infection in CF patients post-LTX and as indicators of CLAD  
331 progression. Furthermore, they are relatively easy to detect with LC-MS/MS rapidly after sample



332 extraction. Finally, we note that many of these *P. aeruginosa* small molecules were detected in  
333 the first BALF sample after LTX. This observation supports the hypothesis that the bacterium  
334 readily re-colonizes the respiratory tract post-LTX from its reservoir in the upper airways (i.e.,  
335 paranasal sinuses) [44]. Though data from this study cannot directly assess this infection  
336 reservoir, the detection of quinolones in BALF so early after LTX is an important finding for  
337 understanding the pathogenesis of CLAD.

338

### 339 **Conclusions**

340 The BALF metabolome after lung transplant revealed differences based on underlying lung  
341 disease type and association with final CLAD severity. An important metabolic trend was a shift  
342 in the relative abundance of phosphocholine and phosphoethanolamine lipids that were  
343 predictive of a subject's final CLAD stages with CF. These findings indicate potential predictive  
344 value for the lipid profile as an indicator of disrupted airway surface liquid and impending CLAD  
345 severity. Importantly, our LC-MS/MS approach readily detected virulence metabolites from the  
346 bacterial pathogen *P. aeruginosa*, especially in CF samples, which were associated with poor  
347 CLAD outcomes. This study provides a picture of the molecular transitions within the  
348 transplanted lung from the host and bacterial pathogens that may help understand the  
349 progression of allograft dysfunction and merits further study with more targeted approaches for  
350 the molecules identified.



351 **Acknowledgment**

352 We thank Anthony Schillmiller for his constant support during sample processing in the mass  
353 spectrometry and metabolomics core laboratory at Michigan State University. The CF  
354 Foundation grant HUNTER18ABO and the National Institute of Allergy and Infectious Diseases  
355 (R01AI145925) provided funding.

356 **Author contributions:**

357 R. Hunter and R. Quinn conceptualized the study. K. Mahan performed BALF/CLAD stages  
358 tabulation. C. Martin, T. Wiggen, and R. Quinn performed data acquisition, analysis, and  
359 interpretation. C. Martin, R. Quinn, and R. Hunter wrote the original and final versions of the  
360 manuscript. K. Mahan and M. Hertz edited the manuscript. All authors read and approved the  
361 final manuscript.

362 **Disclosure statement:**

363 All authors in the presented manuscript have no conflicts of interest to disclose.

364 **Sources of funding:**

365 Cystic Fibrosis Foundation (HUNTER18ABO) and National Institutes of Health (R01AI145925).

366

<b>Clinical parameters</b>	<b>AATD</b>	<b>CF</b>	<b>COPD</b>	<b>IPF</b>
<i>Number of subjects</i>	22	46	79	47
<i>Sex ratio (F/M)</i>	0.69 (9/13)	1.20 (25/21)	1.20 (43/36)	0.42 (14/33)
<i>Average of age at LTX (range)</i>	55 (42 – 55)	36 (20 – 54)	59 (44 – 74)	58 (39 – 68)
<i>Average of last recorded FEV<sub>1</sub> (range)</i>	64 (18 - 96)	69 (17 – 100)	65 (23 – 100)	68 (26 – 99)
<i>Average of last recorded CLAD stage (0 to 4)</i>	1.57	1.35	1.62	1.36
<i>Number of subjects with P. aeruginosa (%)</i>	11 (50%)	32 (70%)	7 (5%)	4 (9%)
<i>BALF samples</i>	130	185	362	283
<i>BALF average/subject (range)</i>	5.01 (2-12)	4.02 (1-9)	4.58 (2-9)	6.02 (3-10)
<i>Average of sample collection (years)</i>	2.93	3.33	3.64	4.05

367

368 **Table 1.** Clinical characteristics of subjects (total n=194) and samples (total n=960) collected  
 369 post-LTX grouped by prior underlying disease – alpha-1 anti-trypsin deficiency (AATD), cystic  
 370 fibrosis (CF), chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis  
 371 (IPF). BALF sampling information, microbiology associated with *Pseudomonas aeruginosa*, age  
 372 at transplant (LTX), sex ratio (female/male). The averages of the last recorded forced expiratory  
 373 volume per 1 second expressed as a percent of predicted (%FEV<sub>1</sub>) and the CLAD stage are  
 374 displayed based on pre-transplant diagnoses.

375

376


377

<b>Pairwise Comparisons</b>	<b>F-value</b>	<b>p-value</b>
COPD and IPF	26.5689	0.001
COPD and CF	2.1869	0.002
COPD and IPF	1.7698	0.017
AATD and CF	21.2079	0.001
AATD and IPF	28.6926	0.001
CF and IPF	3.1142	0.001

378 **Table 2** Post-hoc pairwise comparisons of BALF metabolome among different diseases (AATD,  
379 CF, COPD, and IPF).

380


381



382


383 **Figure 1. Lung allograft metabolomic profiles vary by pre-LTX condition.** a) PCoA plot of a  
384 Bray-Curtis distance matrix of lung allograft BALF metabolomic profiles. Samples colored by  
385 pre-LTX disease and demonstrate significant differences among disease types (PERMANOVA,  
386  $F=3.91$ ,  $p = 0.001$ , random forest out-of-bag (OOB) error = 41.03%). b) Feature abundance of  
387 DL-Phenylalanine by disease state. Kruskal-Wallis test and post-hoc Dunn test p-values are  
388 shown. c) Uniqueness and sharing of BALF metabolites across diseases. Molecule presence or  
389 absence was determined and plotted by the number of molecules that are unique, shared with  
390 one other, two others, or all four diseases. d) Ranking molecular abundance curves of BALF  
391 metabolome colored by disease.

392



393

394 **Figure 2.** Principal coordinate analysis plots of Bray-Curtis distance matrices calculated for  
395 BALF metabolome based on CLAD stage measurements: Statistics from the categorical  
396 PERMANOVA testing (F and p-value) and linear variation based on the RF analysis (%Var) are  
397 shown for each plot. a) PCoA plot of the entire BALF metabolome colored by the final CLAD  
398 stages. b) PCoA plots of the entire BALF metabolomic data separated by disease type colored  
399 by the final CLAD stages.





400  
 401 **Figure 3** a) Scatter plots and linear regression analysis of feature abundances of target  
 402 molecules lysoPE (18:0/0:0), lysoPE (18:1/0:0), PC (16:0/14:0), PC( 16:0/18:0), and HHQ for all  
 403 diseases against the final BOS-grade. Statistics of the linear regression are shown on the plots.  
 404 b) Box plots of feature abundances of each molecule with final CLAD stages separated by  
 405 individual diseases (AATD, CF, COPD, IPF). Pearson correlation test (R) is displayed, and \*\*\* =  
 406 p values  $\leq 0.001$ .





It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).



408  
409 Figure 4. *Pseudomonas*-derived molecules in subjects that underwent lung transplant due to CF  
410 disease. A) Molecular networks of microbial molecules produced by *Pseudomonas* sp. that were  
411 identified by GNPS library searching. Each node represents a unique MS/MS spectrum  
412 (putative molecule), and connections between nodes are determined by spectral similarity

413 (cosine score) from MS/MS alignment. Pie charts represent total feature abundance colored by  
414 the underlying disease. B) Percentage of samples that displayed *Pseudomonas*-like molecules  
415 in subjects with CF across longitudinal BALF sampling time points and C) dynamics among  
416 subjects over time. D) Linear correlation plot displaying the abundance of selected  
417 *Pseudomonas* molecules post-LTX and E) its relation to *Pseudomonas spp.* relative abundance  
418 in samples.  
419





420 **References**

- 421 1 Afonso JE, Júnior, de Campos Werebe E, *et al.* Lung transplantation. *Einstein*  
422 2015;**13**:297.
- 423 2 Yusen RD. Technology and Outcomes Assessment in Lung Transplantation. Proceedings  
424 of the American Thoracic Society. 2009;**6**:128–36. doi:10.1513/pats.200809-102go
- 425 3 Chambers DC, Cherikh WS, Goldfarb SB, *et al.* The International Thoracic Organ  
426 Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-  
427 fifth adult lung and heart-lung transplant report-2018; Focus theme: Multiorgan  
428 Transplantation. *J Heart Lung Transplant* 2018;**37**:1169–83.
- 429 4 Tissot A, Danger R, Clautre J, *et al.* Early Identification of Chronic Lung Allograft  
430 Dysfunction: The Need of Biomarkers. *Front Immunol* 2019;**10**.  
431 doi:10.3389/fimmu.2019.01681
- 432 5 DerHovanessian A, Wallace WD, Lynch JP 3rd, *et al.* Chronic Lung Allograft Dysfunction:  
433 Evolving Concepts and Therapies. *Semin Respir Crit Care Med* 2018;**39**:155–71.
- 434 6 Verleden GM, Glanville AR, Lease ED, *et al.* Chronic lung allograft dysfunction: Definition,  
435 diagnostic criteria, and approaches to treatment- A consensus report from the Pulmonary  
436 Council of the ISHLT. *J Heart Lung Transplant* 2019;**38**:493–503.
- 437 7 Conrad A, Janciauskiene S, Köhnlein T, *et al.* Impact of alpha 1-antitrypsin deficiency and  
438 prior augmentation therapy on patients' survival after lung transplantation. *Eur Respir J*  
439 2017;**50**. doi:10.1183/13993003.00962-2017
- 440 8 Kneidinger N, Milger K, Janitza S, *et al.* Lung volumes predict survival in patients with  
441 chronic lung allograft dysfunction. *Eur Respir J* 2017;**49**. doi:10.1183/13993003.01315-  
442 2016
- 443 9 Fernandez IE, Heinzelmann K, Verleden S, *et al.* Characteristic patterns in the fibrotic lung.  
444 Comparing idiopathic pulmonary fibrosis with chronic lung allograft dysfunction. *Ann Am*  
445 *Thorac Soc* 2015;**12 Suppl 1**:S34–41.
- 446 10 Joshua Blatter SS. Lung Transplantation in Cystic Fibrosis: Trends and Controversies.  
447 *Pediatr Allergy Immunol Pulmonol* 2015;**28**:237.
- 448 11 Walmsley S, Cruickshank-Quinn C, Quinn K, *et al.* A prototypic small molecule database for  
449 bronchoalveolar lavage-based metabolomics. *Sci Data* 2018;**5**:180060.
- 450 12 Das S, Bernasconi E, Koutsokera A, *et al.* A prevalent and culturable microbiota links  
451 ecological balance to clinical stability of the human lung after transplantation. *Nat Commun*  
452 2021;**12**:2126.
- 453 13 Combs MP, Wheeler DS, Luth JE, *et al.* Lung microbiota predict chronic rejection in healthy

- 454 lung transplant recipients: a prospective cohort study. *Lancet Respir Med* 2021;**9**:601–12.
- 455 14 Evans CR, Karnovsky A, Kovach MA, *et al.* Untargeted LC-MS metabolomics of  
456 bronchoalveolar lavage fluid differentiates acute respiratory distress syndrome from health.  
457 *J Proteome Res* 2014;**13**:640–9.
- 458 15 Cribbs SK, Park Y, Guidot DM, *et al.* Metabolomics of bronchoalveolar lavage differentiate  
459 healthy HIV-1-infected subjects from controls. *AIDS Res Hum Retroviruses* 2014;**30**:579–  
460 85.
- 461 16 Watzenboeck ML, Gorki A-D, Quattrone F, *et al.* Multi-omics profiling predicts allograft  
462 function after lung transplantation. *Eur Respir J* 2022;**59**. doi:10.1183/13993003.03292-  
463 2020
- 464 17 Walter S, Gudowius P, Bosshammer J, *et al.* Epidemiology of chronic *Pseudomonas*  
465 *aeruginosa* infections in the airways of lung transplant recipients with cystic fibrosis. *Thorax*  
466 1997;**52**:318–21.
- 467 18 da Silva RR, Lopes NP, Silva DB. CHAPTER 3:Metabolomics. In: *Mass Spectrometry in*  
468 *Chemical Biology*. 2017. 57–81.
- 469 19 Garg N, Kapon C, Lim YW, *et al.* Mass spectral similarity for untargeted metabolomics  
470 data analysis of complex mixtures. *Int J Mass Spectrom* 2015;**377**:719–717.
- 471 20 Quinn RA, Nothias L-F, Vining O, *et al.* Molecular Networking As a Drug Discovery, Drug  
472 Metabolism, and Precision Medicine Strategy. *Trends Pharmacol Sci* 2017;**38**:143–54.
- 473 21 Wang M, Carver JJ, Phelan VV, *et al.* Sharing and community curation of mass  
474 spectrometry data with Global Natural Products Social Molecular Networking. *Nat*  
475 *Biotechnol* 2016;**34**:828–37.
- 476 22 Nothias L-F, Petras D, Schmid R, *et al.* Feature-based molecular networking in the GNPS  
477 analysis environment. *Nat Methods* 2020;**17**:905–8.
- 478 23 Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. *Am J Respir*  
479 *Crit Care Med* 2002;**166**:440–4.
- 480 24 Pluskal T, Castillo S, Villar-Briones A, *et al.* MZmine 2: modular framework for processing,  
481 visualizing, and analyzing mass spectrometry-based molecular profile data. *BMC*  
482 *Bioinformatics* 2010;**11**:395.
- 483 25 Vázquez-Baeza Y, Pirrung M, Gonzalez A, *et al.* EMPeror: a tool for visualizing high-  
484 throughput microbial community data. *Gigascience* 2013;**2**:16.
- 485 26 Wickham H, Hester J, Chang W. Devtools: Tools to make developing r packages easier. *R*  
486 *package version*
- 487 27 Oksanen J, Kindt R, Legendre P, *et al.* The vegan package. *Community ecology package*


- 488 2007;**10**:719.
- 489 28 Lucas SK, Villarreal AR, Ahmad MM, *et al.* Anaerobic Microbiota Derived from the Upper  
490 Airways Impact Staphylococcus aureus Physiology. *Infect Immun* 2021;**89**:e0015321.
- 491 29 Callahan BJ, McMurdie PJ, Rosen MJ, *et al.* DADA2: High-resolution sample inference  
492 from Illumina amplicon data. *Nat Methods* 2016;**13**:581–3.
- 493 30 Raghuvanshi R, Vasco K, Vázquez-Baeza Y, *et al.* High-Resolution Longitudinal Dynamics  
494 of the Cystic Fibrosis Sputum Microbiome and Metabolome through Antibiotic Therapy.  
495 *mSystems* 2020;**5**. doi:10.1128/mSystems.00292-20
- 496 31 Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. Springer 2016.
- 497 32 Oksanen J, Blanchet FG, Kindt R, *et al.* Vegan: community ecology package. R package  
498 version 1.17-4. <http://cran.r-project.org>> Acesso em 2010;**23**:2010.
- 499 33 Barr HL, Halliday N, Cámara M, *et al.* Pseudomonas aeruginosa quorum sensing  
500 molecules correlate with clinical status in cystic fibrosis. *Eur Respir J* 2015;**46**:1046.
- 501 34 da Silva RR, Dorrestein PC, Quinn RA. Illuminating the dark matter in metabolomics. *Proc.*  
502 *Natl. Acad. Sci. U. S. A.* 2015;**112**:12549–50.
- 503 35 Hoffmann MA, Nothias L-F, Ludwig M, *et al.* High-confidence structural annotation of  
504 metabolites absent from spectral libraries. *Nat Biotechnol* 2022;**40**:411–21.
- 505 36 Jarmusch AK, Wang M, Aceves CM, *et al.* ReDU: a framework to find and reanalyze public  
506 mass spectrometry data. *Nat Methods* 2020;**17**:901–4.
- 507 37 Ernst M, Kang KB, Caraballo-Rodríguez AM, *et al.* MolNetEnhancer: Enhanced Molecular  
508 Networks by Integrating Metabolome Mining and Annotation Tools. *Metabolites* 2019;**9**.  
509 doi:10.3390/metabo9070144
- 510 38 Berkebile AR, McCray PB, Jr. Effects of airway surface liquid pH on host defense in cystic  
511 fibrosis. *Int J Biochem Cell Biol* 2014;**52**:124.
- 512 39 Nkadi PO, Allen Merritt T, Pillers D-AM. An overview of pulmonary surfactant in the  
513 neonate: Genetics, metabolism, and the role of surfactant in health and disease. *Molecular*  
514 *Genetics and Metabolism*. 2009;**97**:95–101. doi:10.1016/j.ymgme.2009.01.015
- 515 40 Chen Z, Zhong M, Luo Y, *et al.* Determination of rheology and surface tension of airway  
516 surface liquid: a review of clinical relevance and measurement techniques. *Respir Res*  
517 2019;**20**:1–14.
- 518 41 Anandan A, Evans GL, Condic-Jurkic K, *et al.* Structure of a lipid A phosphoethanolamine  
519 transferase suggests how conformational changes govern substrate binding. *Proc Natl*  
520 *Acad Sci U S A* 2017;**114**:2218.
- 521 42 Sohlenkamp C, Geiger O. Bacterial membrane lipids: diversity in structures and pathways.

- 522 *FEMS Microbiol Rev* 2016;**40**:133–59.
- 523 43 Smith EE, Buckley DG, Wu Z, *et al.* Genetic adaptation by *Pseudomonas aeruginosa* to the  
524 airways of cystic fibrosis patients. *Proc Natl Acad Sci U S A* 2006;**103**.  
525 doi:10.1073/pnas.0602138103
- 526 44 Syed SA, Whelan FJ, Waddell B, *et al.* Reemergence of Lower-Airway Microbiota in Lung  
527 Transplant Patients with Cystic Fibrosis. *Ann Am Thorac Soc* 2016;**13**:2132–42.
- 528 45 McCort M, MacKenzie E, Pursell K, *et al.* Bacterial infections in lung transplantation. *J*  
529 *Thorac Dis* 2021;**13**:6654–72.
- 530 46 Migiyama Y, Kaneko Y, Yanagihara K, *et al.* Efficacy of AiiM, an N-acylhomoserine  
531 lactonase, against *Pseudomonas aeruginosa* in a mouse model of acute pneumonia.  
532 *Antimicrob Agents Chemother* 2013;**57**. doi:10.1128/AAC.00456-13  
533






a)




b)




It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).


A)



B)



A)



### Quinolones nomenclature

HQNO: 2-heptyl-4-quinolone-N-oxide  
HNQ: 2-nonyl-4-quinolone  
HHQ: 4-hydroxy-2-heptylquinolone


### Color information in sub-networks

Pie chart colors represents feature abundance based on diseases


■ AATD ■ CF ■ COPD ■ IPF

Annotated by GNPS: ● Edge width represent spectral similarity between nodes (cosine score) | 0.70 - 1.00 |


B)




C)



D)



E)



### Patient ID

